Abstract 493P
Background
Mediastinal lymph node dissection (MLND) is a crucial procedure during non-small cell lung cancer (NSCLC) resection, but the prognostic value of 4L lymph node dissection ( 4L-LND) continues to be controversial. Here, we conducted this systematic review and meta-analysis to evaluate the associations of 4L-LND with short- and long- term survival outcomes in surgically treated NSCLC patients.
Methods
We systematically searched studies from PubMed, Embase, and the Corchrane Library up to May 1, 2023. Studies investigating the prognostic value of 4L-LND and non-4L-LND on NSCLC survival were included. Data for analysis mainly included postoperative complications, overall survival (OS) and disease-free survival (DFS). We used the Newcastle-Ottawa Scale (NOS) to evaluate the quality of the included studies. The Q-test and I2-test were used to assess heterogeneity. The stability of pooled HRs was examined by sensitivity analysis.
Results
ix retrospective studies with a total of 4565 NSCLC patients who received 4L-LND or did not receive 4L-LND were included. The 4L-LND group had a significantly better OS (HR = 0.75, 95% CI: 0.61–0.91, P = 0.004) and DFS (HR = 0.76, 95% CI: 0.66–0.88, P = 0.0002) than the non-4L-LND group, especially in the subgroup analysis of PSM studies. Although no significant difference in chest tube drainage for more than 7 days rate (RR = 0.98, 95% CI: 0.31–3.08, P = 0.97), hoarseness rate (RR = 1.60, 95% CI: 0.53–4.87, P = 0.51), and chylothorax rate (RR = 1.28, 95% CI: 0.58–2.84, P = 0.54) was observed, however, those who received 4L-LND had a higher total postoperative complication rate than those who did not (RR = 1.35, 95% CI: 1.09–1.67, P = 0.006). There was no significant heterogeneity during our analysis, and no potential publication bias was observed among these studies.
Conclusions
Our meta-analysis showed that the 4L-LND group was significantly associated with both survival outcomes and postoperative complications compared to the non-4L-LND group in treating NSCLC patients. However, more prospective clinical trials should be well-designed to evaluate our conclusion due to the lack of guideline surpport.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
W. Li.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract
580P - Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor <italic>(EGFR)</italic> 21L858R mutation: A multicenter, ambispective, consecutive case-series study
Presenter: Shouzheng Wang
Session: Poster Display
Resources:
Abstract